1
|
Imbs DC, El Cheikh R, Boyer A, Ciccolini J, Mascaux C, Lacarelle B, Barlesi F, Barbolosi D, Benzekry S. Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY 2017; 7:42-50. [PMID: 29218795 PMCID: PMC5784740 DOI: 10.1002/psp4.12265] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/27/2017] [Revised: 10/25/2017] [Accepted: 10/30/2017] [Indexed: 12/20/2022]
Abstract
Concomitant administration of bevacizumab and pemetrexed‐cisplatin is a common treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC). Vascular normalization following bevacizumab administration may transiently enhance drug delivery, suggesting improved efficacy with sequential administration. To investigate optimal scheduling, we conducted a study in NSCLC‐bearing mice. First, experiments demonstrated improved efficacy when using sequential vs. concomitant scheduling of bevacizumab and chemotherapy. Combining this data with a mathematical model of tumor growth under therapy accounting for the normalization effect, we predicted an optimal delay of 2.8 days between bevacizumab and chemotherapy. This prediction was confirmed experimentally, with reduced tumor growth of 38% as compared to concomitant scheduling, and prolonged survival (74 vs. 70 days). Alternate sequencing of 8 days failed in achieving a similar increase in efficacy, thus emphasizing the utility of modeling support to identify optimal scheduling. The model could also be a useful tool in the clinic to personally tailor regimen sequences.
Collapse
Affiliation(s)
| | - Raouf El Cheikh
- SMARTc Unit, Inserm S_911 CRO2, Aix-Marseille University, Marseille, France
| | - Arnaud Boyer
- SMARTc Unit, Inserm S_911 CRO2, Aix-Marseille University, Marseille, France.,Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - Joseph Ciccolini
- SMARTc Unit, Inserm S_911 CRO2, Aix-Marseille University, Marseille, France
| | - Céline Mascaux
- SMARTc Unit, Inserm S_911 CRO2, Aix-Marseille University, Marseille, France.,Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - Bruno Lacarelle
- SMARTc Unit, Inserm S_911 CRO2, Aix-Marseille University, Marseille, France
| | - Fabrice Barlesi
- SMARTc Unit, Inserm S_911 CRO2, Aix-Marseille University, Marseille, France.,Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | | | - Sébastien Benzekry
- MONC Team, Inria Bordeaux Sud-Ouest, Talence, France.,Institut de Mathématiques de Bordeaux, UMR 5251, University of Bordeaux and CNRS, Talence, France
| |
Collapse
|